C4 Therapeutics, Inc. (CCCC) bonds
CCCCNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3018% above fair value
$2.76−0.01 (-0.36%)
Close on Nov 13, 2026Market cap $339.55MP/E –Yield –
Debt
Borrowings on the balance sheet, Sep 30, 2026
C4 Therapeutics reports no long-term debt line
Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2022
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in C4 Therapeutics's 10-K for the period ended Jun 5, 2020
C4 Therapeutics's filings do not break debt down by note
The debt footnote in the annual report has no machine-readable detail for individual notes, so coupons and maturities cannot be listed. The repayment schedule above comes from the same report.
Credit facilities
Revolving credit lines and other committed borrowing capacity
| Facility | Size |
|---|---|
| Term Loan | $20.00M |
See a number that looks wrong?